About neumora therapeutics inc - NMRA
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
NMRA At a Glance
Neumora Therapeutics, Inc.
260 Arsenal Place
Watertown, Massachusetts 02472
| Phone | 1-857-760-0900 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -243,787,000.00 | |
| Sector | Health Technology | Employees | 110 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
NMRA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.971 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.26 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.001 |
NMRA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,216,245.455 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NMRA Liquidity
| Current Ratio | 10.508 |
| Quick Ratio | 10.508 |
| Cash Ratio | 10.332 |
NMRA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -59.96 |
| Return on Equity | -64.482 |
| Return on Total Capital | -84.38 |
| Return on Invested Capital | -64.324 |
NMRA Capital Structure
| Total Debt to Total Equity | 0.646 |
| Total Debt to Total Capital | 0.641 |
| Total Debt to Total Assets | 0.585 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |